OWL-LABS
23.6.2021 01:03:07 CEST | Business Wire | Press release
Research conducted by Owl Labs , which polled 2000 business leaders* based in the UK, Germany, France, and the Nordics** shows that just 11% of business leaders expect their employees to return to the office full-time, indicating a more permanent shift to hybrid working. What’s more, the majority of European organisations (92%) are keen to explore progressive policies post-pandemic including introducing working from anywhere (42%), core working hours (39%), a four-day week (39%), and unlimited holiday (22%). When considering why employers are permanently moving to a more flexible work model, profitability plays an important role. Close to two-thirds (62%) of European business leaders reported that hybrid working makes companies more profitable with Enterprise businesses (1000+ employees) the most likely to think so (73%) versus small and medium-sized companies (55%).
As businesses continue to adapt to working in a Covid-19 environment, over a third (39%) of European business leaders anticipate that Covid-19 will continue to impact the running of their business for up to six months. French business leaders are the most optimistic with one in five (20%) believing Covid-19 would only impact the running of their office for the next three months or less. However, the majority believe that remote and hybrid working has positively impacted their business, with the majority stating it had impacted employee wellbeing (52%) and business costs (50%) positively.
With a growing desire to support employees' partial return-to-office, one in four EU organisations (24%) are now planning to enforce ‘vaccine passports’ and only allow those who have been vaccinated into the office. Germany is the most cautious with 31% of business leaders insisting on Covid-19 vaccines, while 23% of business leaders in the UK, 21% in the Nordics and 19% in France intend to enforce vaccines. Additionally, over a third (38%) of EU business leaders are considering providing onsite Covid-19 testing facilities to encourage employees to return to work, with French and German organisations most likely to provide onsite testing facilities at 42% and 43% respectively.
European organisations are already planning ahead to a post-pandemic work environment, with the majority of business leaders (63%) aiming to maintain the same amount of office space, even with the rise of hybrid work. Just 11% are planning to get rid of their offices entirely (rising to 14% in the Nordics). When it comes to hiring, one-third of EU organisations (32%) plan to hire employees who can work remotely, based on skill, rather than their proximity to an office. In a move that may not be welcomed by employees, 29% of business leaders plan to use productivity apps to monitor activity of remote employees. This rises steeply in Germany, where 37% of business leaders plan on utilising productivity and activity monitoring of remote employees, compared to just 22% of Nordic business leaders.
As businesses move to hybrid and flexible working, technology plays a crucial role in enabling this shift. As a result, the majority (93%) of European organisations are putting workplace policies and infrastructure in place to prepare for a post-pandemic workplace. This includes nearly half (42%) of European businesses investing in new tech and solutions to support a hybrid workforce. The UK leads the tech charge with 43% investing in communications tools (such as Slack, Zoom, and Meeting Owl conference cameras) compared to 28% in the Nordics, 36% in France and 38% in Germany. The primary activities companies are carrying out to prepare their workplaces now and post-pandemic are:
○ Investing in communication tools and technology (Slack, Zoom, conference cameras, Meeting Owls, etc.) (36%)
○ Continued social-distancing measures for employees in the office (35%)
○ Providing at-home and in-office equipment for employees so they can easily work from both locations (33%)
Frank Weishaupt, CEO of Owl Labs says, “It’s encouraging to see business leaders across Europe embrace hybrid work post-pandemic. As organisations have adapted to working remotely, they’ve seen the benefits. The ability to hire remote teams from anywhere, leverage new technologies whilst saving on costs. We know that technology will continue to play a key role in supporting this permanent shift to hybrid work, and businesses that will be successful will create the infrastructure and workplace policies that enable their employees to maintain high levels of creativity and collaboration, wherever they dial-in from.”
---ends---
Methodology:
* Business Leaders refer to C-suite executives, heads of departments, HR managers and general managers
**The Nordics refers to Sweden, Finland, Norway & Denmark
About Owl Labs
Owl Labs is a collaborative technology company dedicated to creating a better workplace and learning experience for today's hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl Pro , features a wifi-enabled, portable 360° camera, mic, and speaker with proprietary AI technology that automatically focuses on who is speaking using audio and visual cues. The company is a recipient of TIME’s Best Inventions of 2020 and is dedicated to providing collaborative and productivity solutions for organizations to stay connected to their remote employees and educators to stay connected to their remote students, regardless of location. Learn more at www.owllabs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
